Trends in breast cancer during three decades in Denmark: Stage at diagnosis, surgical management and survival

References

• Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol 1988; 27: 627–47
   PubMed Web of Science ®Google Scholar
• DBCG- Danish Breast Cancer Cooperative Group. 1998. DBCG, Copenhagen.
   Google Scholar
• Jensena AR, Ewertz M, Cold S, Storm HH, Overgaard J. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur J Cancer 2003; 39: 1783–93
   PubMed Web of Science ®Google Scholar
• Andreasen AH, Andersen KW, Madsen M, Mouridsen H, Olesen KP, Lynge E. Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening. Br J Cancer 1994; 70: 133–7
   PubMed Web of Science ®Google Scholar
• Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M, et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 239–47
   PubMed Web of Science ®Google Scholar
• Key indicators. Statistics Denmark, www.dst.dk. 2007.
   Google Scholar
• Grabau DA, Jensen MB, Blichert-Toft M, Andersen JA, Dyreborg U, Carstensen B, et al. The importance of surgery and accurate axillary staging for survival in breast cancer. Eur J Surg Oncol 1998; 24: 499–507
   PubMed Web of Science ®Google Scholar
• Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 1997; 44: 535–9
   PubMed Web of Science ®Google Scholar
• Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002; 11: 359–64
   PubMed Web of Science ®Google Scholar
• Jensen AR, Storm HH, Moller S, Overgaard J. Validity and representativity in the Danish Breast Cancer Cooperative Group–a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol 2003; 42: 179–85
   PubMed Web of Science ®Google Scholar
• UICC. TNM classification of malignant tumours, 5th ed. 1997.
   Google Scholar
• Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23: 51–64
   PubMed Web of Science ®Google Scholar
• van der Heiden-van der, Loo, Bezemer, PD, Hennipman, A, Siesling, S, van Diest, PJ, Bongers, V, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006;32:710–4.
   PubMedGoogle Scholar
• Madsen, AH, Jensen, AR, Christiansen, P, Garne, JP, Cold, S, Ewertz, M, et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study from the Danish Breast Cancer Cooperative Group. Acta Oncol 2007.
   Google Scholar
• Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604–8
   PubMed Web of Science ®Google Scholar
• Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659–67
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000; 355: 1822
   PubMed Web of Science ®Google Scholar
• Eaker S, Dickman PW, Hellstrom V, Zack MM, Ahlgren J, Holmberg L. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev 2005; 14: 2914–8
   PubMed Web of Science ®Google Scholar
• DBCG. Guidelines from the Danish Breast Cancer Cooperative Group.; www.dbcg.dk.
   Google Scholar
• Joensuu H, Ejlertsen B, Lonning PE, Rutqvist LE. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol 2005; 44: 23–31
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369: 559–70
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24: 2268–75
   PubMed Web of Science ®Google Scholar